Navigation Links
Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
Date:12/22/2009

SAN DIEGO, Dec. 22, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients.

William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer, stated, "Physicians need new, better-tolerated approaches to improve the treatment of patients who are obese or significantly overweight. Based on the robust data package we submitted to the FDA, lorcaserin has the potential to meet this need, offering patients the opportunity to achieve sustainable weight loss in a well-tolerated manner and improve their cardiometabolic health and quality of life."

The pivotal Phase 3 clinical trial program, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) and BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management), evaluated nearly 7,200 patients treated for up to two years and showed that lorcaserin consistently produced significant weight loss with excellent safety and tolerability.

"Today's NDA submission is an important milestone towards realizing lorcaserin's significant commercial potential, and we are excited by the possibility of bringing lorcaserin to patients who need help in managing their weight," said Jack Lief, Arena's President and Chief Executive Officer. "Physician feedback suggests that, if approved, lorcaserin's combination of efficacy, safety and tolerability will position the drug candidate a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- VWR (NASDAQ: VWR ), a leading, ... redesign of its global website, www.vwr.com , to improve ... new site, guests will enjoy enhanced content on a modern ... country site now includes: , a simplified ... , the ability to search by discipline/industry. ...
(Date:8/3/2015)... August 3, 2015 /OFF ... Group LLC, PIV757417 The following release: "Biotech Advancements ... Drug Products & Treatments for Critical-Care Patients With ... time: 3 Aug 2015 12:30 GMT ... military surgical research and top-tier universities for identifying ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health Food Grocers ... , “Our ‘Ask a Nutritionist’ feature on our website is a free service to ... Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food Grocers’ website offers ...
(Date:8/3/2015)... ... ... to an opinion piece published July 28 by the Washington Post, the conventional ... loss may not be accurate. While this system may work for some people, the author ... based both on the individual and at what point that person is in their weight ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... FL (PRWEB) , ... August ... ... most-visited bodybuilding and fitness site and the largest online retailer of nutritional ... Awards. BPI Sports is up for 11 awards in the following categories:, ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show widespread ... percent of respondents said they agreed or strongly agreed that the controversial law ...
Breaking Medicine News(10 mins):Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3
... to Stem Spread of HIV and Challenge StigmaMENLO ... of leading media companies from Latin America announced ... sobre el SIDA (IMLAS) -- the first Latin ... follows a meeting last month held in conjunction ...
... COLUMBIA, S.C., Feb. 18 /PRNewswire-USNewswire/ -- ... today that its individual clients and U.S. employer ... on surgery and other medical care while remaining ... said his company has accepted the CIMA Hospitals ...
... Columbia, Feb. 18 ,Allscripts announced today that Edge ... to resell the Allscripts Electronic,Health Record as "EdgeEHR(TM) ... currently use practice management software on the Mac ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) , ...
... to Personalized Screening of Anti-Rejection Drug DosingCINCINNATI, Feb. ... that helps the body metabolize a kidney transplant ... higher risk for side effects, including compromised white ... new research.Published online Feb. 18 by the Nature ...
... winners of the MetLife Foundation Awards for Medical ... Washington, D.C. today, at a scientific briefing and luncheon that ... understanding of Alzheimer,s and the substances in the brain that ... Michael S. Wolfe , Ph.D., professor of neurology at ...
... Gene Function to Double Survival and Increase Transfusion IndependenceCROSSWICKS, ... Myelodysplastic Syndromes (MDS) Foundation says data published in the ... confirms VIDAZA extends survival for patients with higher-risk MDS. ... are difficult to treat and in higher-risk patients have ...
Cached Medicine News:Health News:Top Latin American Television Companies Commit to Addressing AIDS 2Health News:Top Latin American Television Companies Commit to Addressing AIDS 3Health News:Top Latin American Television Companies Commit to Addressing AIDS 4Health News:Companion Global Healthcare Expands Service to Include Hospitals in Mexico 2Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 2Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 3Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 4Health News:Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform 5Health News:Gene Mutation Increases Drug Toxicity, Rejection Risk in Pediatric Kidney Transplants 2Health News:Gene Mutation Increases Drug Toxicity, Rejection Risk in Pediatric Kidney Transplants 3Health News:Gene Mutation Increases Drug Toxicity, Rejection Risk in Pediatric Kidney Transplants 4Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 2Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 3Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 4Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 5Health News:Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease 6Health News:Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: